{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:05:43Z","timestamp":1784549143509,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.esmoop.2026.108246","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:47:24Z","timestamp":1783442844000},"page":"108246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of durvalumab plus gemcitabine\u2013cisplatin in combined hepatocellular-cholangiocarcinoma versus cholangiocarcinoma"],"prefix":"10.1016","volume":"11","author":[{"given":"C.-C.","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.-Y.","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-F.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-F.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9360-908X","authenticated-orcid":false,"given":"H.-W.","family":"Kou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0680-796X","authenticated-orcid":false,"given":"Y.-F.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-T.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-N.","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-E.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.-K.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-H.","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3173-3242","authenticated-orcid":false,"given":"C.-C.","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8163-1959","authenticated-orcid":false,"given":"C.-L.","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.-W.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5547-409X","authenticated-orcid":false,"given":"C.-H.","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.-L.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-C.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2532-7328","authenticated-orcid":false,"given":"T.-C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9756-3974","authenticated-orcid":false,"given":"J.-S.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.-S.","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0361-4548","authenticated-orcid":false,"given":"W.-C.","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2026.108246_bib1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2026.108246_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.esmoop.2026.108246_bib3","first-page":"15","article-title":"Recent 5-year trends in biliary tract cancer survival rates: an analytical big data survey","volume":"5","author":"Lee","year":"2025","journal-title":"Med Int (Lond)"},{"key":"10.1016\/j.esmoop.2026.108246_bib4","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108246_bib5","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.esmoop.2026.108246_bib6","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jhep.2025.05.003","article-title":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","volume":"83","author":"Oh","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.esmoop.2026.108246_bib7","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2026.108246_bib8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1055\/s-0039-3402515","article-title":"A review on the update of combined hepatocellular cholangiocarcinoma","volume":"40","author":"Komuta","year":"2020","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.esmoop.2026.108246_bib9","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jhep.2024.06.004","article-title":"Rare primary liver cancers: an EASL position paper","volume":"81","author":"Wege","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.esmoop.2026.108246_bib10","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/jjco\/hyaf029","article-title":"Diagnosis, clinical characteristics, and treatment of combined hepatocellular-cholangiocarcinoma","volume":"55","author":"Terashima","year":"2025","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108246_bib11","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1007\/s00535-022-01920-5","article-title":"The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry","volume":"57","author":"Satake","year":"2022","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.esmoop.2026.108246_bib12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.7150\/ijms.50883","article-title":"The clinical characteristics and prognostic factors of combined hepatocellular carcinoma and cholangiocarcinoma, hepatocellular carcinoma and intrahepatic cholangiocarcinoma after surgical resection: a propensity score matching analysis","volume":"18","author":"Tang","year":"2021","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.esmoop.2026.108246_bib13","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1245\/s10434-012-2328-0","article-title":"Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis","volume":"19","author":"Yin","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.esmoop.2026.108246_bib14","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/hepr.13953","article-title":"Report of the 23rd nationwide follow-up survey of primary liver cancer in Japan (2014-2015)","volume":"53","author":"Iijima","year":"2023","journal-title":"Hepatol Res"},{"key":"10.1016\/j.esmoop.2026.108246_bib15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000530700","article-title":"Combined hepatocellular-cholangiocarcinoma: biology, diagnosis, and management","volume":"13","author":"Ye","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.esmoop.2026.108246_bib16","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.amjsurg.2004.03.018","article-title":"Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma","volume":"189","author":"Koh","year":"2005","journal-title":"Am J Surg"},{"key":"10.1016\/j.esmoop.2026.108246_bib17","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/1097-0142(19850101)55:1<124::AID-CNCR2820550120>3.0.CO;2-Z","article-title":"Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study","volume":"55","author":"Goodman","year":"1985","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2026.108246_bib18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jfma.2019.02.012","article-title":"Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection","volume":"119","author":"Chi","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.esmoop.2026.108246_bib19","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/cncr.10392","article-title":"Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors","volume":"94","author":"Jarnagin","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2026.108246_bib20","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/jgh.14547","article-title":"Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers","volume":"34","author":"Wakizaka","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.esmoop.2026.108246_bib21","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/jso.27955","article-title":"Prognostic impact of the cholangiolar component in combined hepatocellular-cholangiocarcinoma: insights from a Western single-center study","volume":"131","author":"Nolasco","year":"2025","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.esmoop.2026.108246_bib22","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/bjc.2017.413","article-title":"Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study","volume":"118","author":"Salimon","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2026.108246_bib23","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1111\/cas.13656","article-title":"Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma","volume":"109","author":"Kobayashi","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.esmoop.2026.108246_bib24","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.6004\/jnccn.2018.7053","article-title":"Systemic therapy for combined hepatocellular-cholangiocarcinoma: a single-institution experience","volume":"16","author":"Trikalinos","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.esmoop.2026.108246_bib25","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/liv.14813","article-title":"Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular-cholangiocarcinoma","volume":"41","author":"Kim","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.esmoop.2026.108246_bib26","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1159\/000525488","article-title":"Systemic treatments with tyrosine kinase inhibitor and platinum-based chemotherapy in patients with unresectable or metastatic hepatocholangiocarcinoma","volume":"11","author":"Gigante","year":"2022","journal-title":"Liver Cancer"},{"key":"10.1016\/j.esmoop.2026.108246_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.100783","article-title":"Clinical characteristics and outcome of patients with combined hepatocellular-cholangiocarcinoma\u2013a European multicenter cohort","volume":"8","author":"Pomej","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2026.108246_bib28","doi-asserted-by":"crossref","first-page":"7547","DOI":"10.1007\/s00432-023-04704-3","article-title":"Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular-cholangiocarcinoma","volume":"149","author":"Jang","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108246_bib29","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ueg2.12503","article-title":"Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: a multicentric retrospective study","volume":"12","author":"Gigante","year":"2024","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.esmoop.2026.108246_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1234113","article-title":"Case report: atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma","volume":"13","author":"Satake","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2026.108246_bib31","article-title":"Interventional treatment combined with immunotargeted therapy in unresectable combined hepatocellular-cholangiocarcinoma: a real-world retrospective cohort study","volume":"16","author":"Lin","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.esmoop.2026.108246_bib32","series-title":"International Agency for Research on Cancer WHO Classification of Tumours of the Digestive System","year":"2019"},{"key":"10.1016\/j.esmoop.2026.108246_bib33","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2026.108246_bib34","series-title":"Common Terminology Criteria for Adverse Events (CTCAE). Version 5","year":"2025"},{"key":"10.1016\/j.esmoop.2026.108246_bib40","series-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"key":"10.1016\/j.esmoop.2026.108246_bib35","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108246_bib36","first-page":"115","article-title":"A phase II study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma","volume":"26","author":"Parikh","year":"2005","journal-title":"Trop Gastroenterol"},{"key":"10.1016\/j.esmoop.2026.108246_bib37","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.esmoop.2026.108246_bib38","article-title":"Genomic profiling of combined hepatocellular cholangiocarcinoma reveals genomics similar to either hepatocellular carcinoma or cholangiocarcinoma","volume":"5","author":"Murugesan","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2026.108246_bib39","doi-asserted-by":"crossref","DOI":"10.1007\/s00428-025-04172-9","article-title":"Comprehensive molecular profiling of combined hepatocellular carcinoma and cholangiocarcinoma reveals distinct Notch signaling subgroups with prognostic significance","author":"Yang","year":"2025","journal-title":"Virchows Arch"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926021885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926021885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:22:19Z","timestamp":1784546539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926021885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2059702926021885"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108246","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of durvalumab plus gemcitabine\u2013cisplatin in combined hepatocellular-cholangiocarcinoma versus cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108246","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108246"}}